Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
STAT+
Health
The Readout

Novartis upsets the CAR-T, Celgene buys into NASH, & your chance to be a pharma tycoon

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Sept. 1, 2016

Reprints
The READOUT
Alex Hogan/STAT

The Readout for September 01, 2016

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

FDA scolds Amgen over a misleading ad that could…
FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its…
Beware the hype over the Apple Watch heart app.…
Beware the hype over the Apple Watch heart app. The device could do more harm than…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories